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Summary A prognostic index, previously derived in a group of 387 patients with primary breast cancer, has
been recalculated for the same patients with over 5 years further follow-up and shown to be unchanged. The
prognostic index has also been applied prospectively to a further group of 320 patients and shown to be
similarly effective in identifying patients with either a very good or a very poor prognosis. It has been verified
that the index applies to patients with primary breast cancer. Patients have now been divided into 5
prognostic groups, predicting 11% of patients with an almost normal survival and a further 10% with a very
poor prognosis. The index is used to stratify patients to study the effects of treatment regimes within groups
of similar patients.
It would be of considerable value in the management of
breast cancer patients to be able to predict more accurately
the clinical course of the disease at the time of initial
treatment. In studies of breast cancer many factors may
appear to indicate prognosis if studied in isolation or in
small groups. To obtain a true indication of the prognostic
importance of these factors it is necessary to employ a form
of multivariate analysis such as that described by Cox (1972)
which can make use of all the data from a group of patients
having a wide range of survival times.
The method was applied to the Nottingham/Tenovus
Breast Cancer Study by Haybittle et al. (1982). Initially nine
factors were recorded for each patient, but the results of the
Cox analysis performed retrospectively showed only three
factors to be significant indicators of prognosis, namely
tumour grade, lymph node stage and tumour size. A further
two factors, menopausal status and oestrogen receptor
content, were approaching significance. A prognostic index
was derived using only the three significant prognostic
factors:
I=0.2 x size +stage+grade.
where size is in cm, stages A, B and C (see below) are coded
1-3 and grade is also coded 1-3.
The index was computed for each patient, who was then
assigned to one of three prognostic groups: Good (1<3.4),
Moderate (3.4 <I< 5.4) and Poor (1> 5.4).
Lifetable analysis of the patients in the Good prognostic
group showed a survival of 88% at 5 years against 21% in
the Poor prognostic group. Since the method of obtaining
the index relied on the best fit to retrospective data it is
essential to perfect the index prospectively.
This paper applies the prognostic index prospectively to a
second group of patients with primary breast cancer who
have presented since since our first report.
The power of the prognostic factors might alter with time,
e.g., factors predicting survival at 10 years might be different
from those predicting 5 year survival. The analysis has been
re-applied to the original group of patients, now with longer
follow-up.
Patients and methods
The patients in the two groups were treated under the care
of a single surgeon (RWB) by simple mastectomy. No
adjuvant systemic therapy or local radiotherapy was used.
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Originial group o,fpatienits w1ith longer followt-up
The prognostic index has been recalculated on the same 387
patients in the report by Haybittle et al. (1982) but now with
a minimum follow-up period of 6 years (range 72-138
months).
Prospectihe group
The prognostic index has been applied prospectively in a
second group of 320 consecutive patients treated over the
subsequent four year period. The longest follow-up time is
six and a half years (range 20-78 months). Lymph node
stage and histological grade were all assessed by the same
pathologist and all patients were under the care of the same
surgeon as the original group. A prognostic index value was
calculated for each patient, who was then assigned to one of
the three prognostic groups.
Method oflanallsis
The relative importance of the prognostic factors was
derived using the multiple regression technique described by
Cox (1972), which derives coefficients (B values) showing
how each factor contributes to the hazard and their
significance (Z values). If Z> 1.96, B is significantly different
from zero at the 5% level in a two-tailed test. Survival
curves have been calculated using the life-table method with
time divided into six-monthly intervals, and differences have
been tested for significance using the test described by
Mantel (1966).
The prognostic factors selected for investigation were
those with a Z value of > 1.5 in the original Cox analysis,
namely menopausal status (a pre-menopausal woman being
either still menstruating or having a plasma sample
containing <50 IU1-l FSH), tumour size measured in the
fresh mastectomy specimen, lymph node involvement judged
by histological examination of node sample by triple node
biopsy technique described elsewhere (Blamey et al., 1980),
tumour grade and oestrogen-receptor (ER) content of the
primary (Haybittle et al., 1982).
Lymph node involvement was classified as:
Stage A: Tumour absent from all three nodes sampled.
Stage B: Tumour in low axillary node only,
Stage C: Tumour in apical axillary and/or internal mammary
node.
Histological grade was determined by a modification of
the Bloom and Richardson criteria (Elston et al., 1982),
under the direction of one pathologist (CWE), and ER
content was assayed at the Tenovus Institute, Cardiff, by the
dextran coated charcoal method (Maynard & Griffiths,
1979). Tumours were classified ER positive if they contained
> 5 fmol specific oestradiol binding mg cytosol protein.
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Results
The B and Z values obtained for the 387 patients in the
original Cox analysis are compared with the new B and Z
values for this group after a longer period of follow-up
(Table I). Stage, size and grade still remain significant
independent prognostic factors of survival with B values
relatively unchanged. The prognostic index derived by
Haybittle et al. (1982) selected two groups which have either
a very good prognosis (I<3.4) or a very poor prognosis
(I>5.4), with about 22% of patients in each of these two
groups (Table II). Lifetable survival curves for each of the
three prognostic groups were also calculated for the
prospective group of patients and compared with those of
the original group (Figure 1). There is a close similarity of
the curves for each prognostic group with no significant
difference between the survival curves in any prognostic
group. There is a significantly higher proportion of patients
in the Good prognostic group (33%) than for the original
study group (Table II).
Table I Values of B and Z obtained by Cox analysis of five
prognostic factors in 387 patients at two different times after
mastectomy
First analysis Second ancalysis
Factor Z B Z B
Menopause 1.5 0.5 0.23 0.22
Tumour size 2.92a 0.17 2.0a 0.11
Lymph stage 5.29b 0.76 5.43b 0.64
Tumour grade 4.56b 0.82 7.71b 0.72
ER content -1.72 -0.34 -1.44 -0.22
Longest survival 6 Years 11 years
ap<0.01; bp<0.00 ; n=387.
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Figure 1 Comparison of survival of patients in the original
(whole lines) and prospective (dotted lines) groups within each of
the three prognostic index groups
Table II Distribution of patients in prognostic
categories for the original and prospective
groups
Prognostic index
Patient
group Good Moderate Poor
Original 87 (23) 214 (55) 86 (22)
Prospective 105 (33) 167 (52) 48 (15)
X2= 13.6(2 ): P< .01
The distribution of prognostic factors in the original and
prospective groups has been compared (Table III). There is
no significant difference in the distribution of lymph node
stage or tumour grade but a significant change in the
distribution of tumour size, with a very much higher
proportion of small tumours in the prospective group.
The distribution of prognostic index values for the
combined study and prospective groups is shown in Figure 2
and indicates that index values lie almost entirely between
the integer values. The survival curves obtained by using the
integer values to separate the new prognostic groups are
shown in Figure 3, demonstrating a ranking order of
survival according to the prognostic index value.
Discussion
The coefficients found by Cox analysis are such that they
obtain the best discrimination for the particular set of data
from which they were derived.
Table III Distribution of significant prognostic factors and index
groups for patients in the original (n=387) and prospective (n=320)
groups
Patient
Factor group Number (%)
Stage A B C
Original 205 (53) 119 (31) 63 (16)
Prospective 185 (61) 76 (25) 59 (14)
A'2 =4.3 (2): NS
Grade I II III
Original 64 (17) 140 (36) 183 (47)
Prospective 60 (19) 137 (43) 123 (38)
2 = 5.6(2°): NS
Size (MM) <20 21-50 >50
Original 151 (39) 189 (49) 47 (12)
Prospective 196 (61) 114 (36) 10 (3)
X2=42(2 ): P<0.001
We have established that the same coefficients continue to
apply to the same group of patients with longer follow-up.
We have also shown that the prognostic index derived from
the coefficients can be applied prospectively to patients
presenting with primary operable breast cancer treated by
simple mastectomy. The close correlation of the survival
curves for patients within each of the prognostic groups
indicates that the Index accurately predicts group survival,
even for those patients with an intermediate Index value.PROGNOSIS IN BREAST CANCER 491
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Figure 2 Distribution of prognostic index values for all patients
(n =707).
The five-year survival obtained by lifetable analysis for all
707 patients is 64%, whereas the five-year survivals for the
Good, Moderate and Poor prognostic groups are 88%, 69%
and 22% respectively. A mortality rate can be estimated for
each group after the first year following treatment. In the
Good group 3% of patients entering a period of one year
will die during the course of that year. In the Moderate
group mortality rate is 7% and in the Poor group it is 30%
p.a.
In the prospective group the proportion of patients
presenting with small tumours is increased when compared
with the original group. This may indicate that women with
breast lumps now seek medical advice earlier. In addition
there has been a programme for the early detection of breast
cancer introduced into Nottingham during the period of
recruitment of the prospective group. In this group, 33% of
patients are in the Good prognostic category and 15% in the
Poor.
Patients with an index value .3, (all grade I, stage A, size-
<20mm) have a survival which is not significantly different
to that of the female age-matched population (P>0.75)
(OPCS, 1981). This group of patients (11%) therefore have
an excellent prognosis (91% survival at 5 years, 88% at 8
years). The index also identifies 10% of patients with an
index value >6, i.e. predominantly grade III, stage C, who
have a very poor survival (17% at 5 years, 7% at 8 years).
This allows us to select a group of patients with an excellent
prognosis after surgery alone, in whom adjuvant therapies
are inappropriate. However, those patients with high index
scores may benefit from local and/or systemic adjuvant
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Figure 3 Survival curves for patients from both original and
prospective groups (n =707) according to integer value of
prognostic index.
therapies,. both in terms of locoregional disease control
(Williams et al., 1985) and possibly survival.
Those patients with intermediate prognostic index values
can now be clearly separated into 3 groups, which should
result in better stratification of patients according to
potential survival than was possible by use of the Good,
Moderate and Poor groups defined previously. The annual
percentage mortality rates for groups 3, 4, 5, 6 and 7 are 1.5,
3.5, 6. 20 and 32 respectively.
The Nottingham prognostic index, therefore, allows us to
accurately predict survival patterns in groups of patients
treated by simple mastectomy. This has enabled us to
compare the outcome of newer treatment modalities, such as
subcutaneous mastectomy with simple mastectomy, after
stratification of patients into prognostic groups (Hinton et
al., 1984). Stratification using this index has allowed us to
offer patients a choice of initial surgery, while still being able
to accurately compare recurrence and survival data for
patients choosing breast conservation with those choosing
simple mastectomy.
We are currently examining other factors which may be of
independent prognostic significance in order to more
accurately predict the survival patterns of individuals within
these defined groups.
The oestrogen receptor status of the primary tumours was analysed
by R.I. Nicholson at the Tenovus Institute, Cardiff. M.R. Williams
is the Tenovus Research Fellow in Surgery.
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